Nanopath

Nanopath is a private, pre-revenue diagnostics company founded in 2018 and based in Cambridge, Massachusetts. The company is commercializing a novel, cartridge-and-reader diagnostic platform that uses surface plasmon resonance (SPR) biosensors to deliver lab-quality, multiplexed results in 10-15 minutes at the point of care, initially targeting women's health. Backed by NIH and NSF grants and led by a technically deep team, Nanopath aims to disrupt the molecular diagnostics paradigm by eliminating the need for complex sample preparation and amplification, enabling same-visit clinical decision-making.

Proprietary point-of-care molecular diagnostic platform utilizing a scalable, robust surface plasmon resonance (SPR) biosensor. It enables rapid (10-15 min), multiplexed detection of biomarkers without nucleic acid amplification, packaged in a low-cost cartridge-and-reader system.

Nanopath competes in the point-of-care molecular diagnostics space against established players like BioFire (bioMérieux) and Cepheid (Danaher), which use PCR-based systems. Its key differentiators are the claimed elimination of amplification for faster results and a potentially lower-cost, highly multiplexed SPR-based platform, but it must prove clinical and commercial viability.